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ABSTRACT
Anemia is the most common hematologic abnormality in patients with human 
immunodeficiency virus (HIV) infection. This abnormality is associated with HIV infection 
itself, HIV-related opportunities infections or drug use. Zidovudine (AZT) is the most 
common cause of anemia in HIV patients. Recent study showed anemia in HIV patients 
is also associated with CD4 cell counts. Aim of this study was to evaluate the risk 
of anemia on HIV patients with different CD4 cell counts after AZT-based antiretroviral 
therapy (ART).This retrospective cohort study was conducted using medical record 
of HIV patients in Dr. Soetomo General Hospital, Surabaya. Subjects who fulfilled the 
inclusion and exclusion criteria were divided into two group i.e. HIV patients with CD4 
cell counts 200-350 cell/mm3 and those with CD4cell counts ≥350 cell/mm
3. All available 
demographics, clinical and laboratory data of subjects before and after AZT-based ART 
were then recorded and evaluated. Ninety-seven HIV patients (50 male and 47 female) 
were involved in this study. The result showed that the anemia incidence significantly 
increased after AZT-based ART (p<0.05), however no significantly different in anemia 
incidence, mean Hb level reduction and Hb level time reduction were observed between 
HIV patients with CD4 cell counts 200-350 cell/mm
3 and those with CD4cell counts 
≥350 cell/mm3(p>0.05). Gender, age, weight and clinical stage were not associated 
with anemia incidence (p>0.05). In contrast, anemia incidence is associated with Hb 
level before AZT therapy (p<0.05). In conclusion, the anemia incidence in HIV patients 
after AZT based ART is not associated with the level of CD4 cell counts, however it is 
associated with Hb levels before AZT therapy.
ABSTRAK
Anemia adalah kelainan hematologi yang paling sering dijumpai pada pasien yang 
terinfeksi human immunodeficiency virus (HIV). Kelainan ini dikaitkan dengan infeksi HIV 
itu sendiri, infeksi oportunitis yang berkaitan dengan HIV dan penggunaan obat. Zidovudin 
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(AZT) adalah penyebab anemia tersering pada pasien HIV. Penelitian terkini menunjukkan 
anemia pada penderita HIV juga dikaitkan dengan kadar CD4 pasien. Penelitian ini 
bertujuan mengkaji risiko anemia pada pasien HIV dengan kadar CD4 yang berbeda setelah 
menerima pengobatan anti retrovirus berbasis AZT. Penelitian cohort retrospective ini 
menggunakan data rekam medik pasien HIV di RSUP Dr. Soetomo, Surabaya. Subjek 
yang memenuhi kriteria inklusi dan eksklusi dibagi menjadi dua kelompok yaitu pasien HIV 
dengan kadar CD4 200-350 sel/mm
3 dan pasien dengan kadar CD4>350 sel/mm
3. Semua 
data demografi, klinik dan laboratorium subjek yang ada sebelum dan sesudah pengobatan 
anti retrovirus berbasis AZT dicatat dan dievaluasi. Sebanyak 97 pasien terdiri dari 50 
laki-laki dan 47 wanita diambil datanya dalam penelitian ini. Hasil penelitian menunjukkan 
kejadian anemia meningkat secara nyata setelah pengobatan AZT pada kedua kelompok 
(p<0,05). Namun demikian, kejadian anemia, rerata penurunan kadar Hb, dan waktu 
penurunan kadar Hb tidak berbeda nyata pada pasien dengan kadar CD4 200-350 sel/
mm3 dan pasien dengan kadar CD4>350 sel/mm
3 (p>0,05). Jenis kelamin, umur dan 
berat badan tidak berkaitan dengan kejadian anemia (p>0,05), akan tetapi kadar Hb 
sebelum pengobatan dengan AZT berkaitan nyata dengan kejadian anemia (p<0,05). 
Dapat disimpulkan, kejadian anemia pada pasien HIV setelah pengobatan anti retrovirus 
berbasis AZT tidak berkaitan dengan kadar CD4 tetapi berkaitan dengan kadar Hb sebelum 
terapai AZT. 
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INTRODUCTION 
Anemia is the most common haemato-
logic abnormality in patients with human 
immunodeficiency virus (HIV) infection. 
Anemia affects 18% of patients with 
asymptomatic HIV-seropositive, 50% of 
those with middle-stage HIV disease and 
75% of those with late-stage HIV disease. 
1,2An obvious cause of anemia in patients with 
HIV infection is blood loss. Other than blood 
loss, the pathophysiology of HIV associated 
anemia may involve decreased red blood cell 
(RBC) production, increased RBC destruction 
and ineffective RBC production.1,3Factors 
associated with anemia in HIV patients 
include HIV infection itself, HIV-related 
opportunities infections or as a consequence 
of drug used for HIV infection and associated 
condition.4,5
Several drugs that commonly cause 
anemia in HIV patients have been reported.1,4,5 
Among these drugs, zidovudine (AZT) is 
probably the most common cause of anemia 
in HIV patients. Zidovudine, a nucleoside 
reverse transcriptase inhibitor (NRTI), is 
one of earliest antiretroviral drugs used as 
a combination in some of the highly active 
antiretroviral therapy (HAART) regimens to 
treat of HIV/AIDS. Moreover, AZT is the first 
drug which was approved by US FDA for use 
in HIV/AIDS.6 Its used, however, is associated 
with hematologic abnormalities especially 
anemia. This anemia is observed in most of 
the patients within 3-6 months of initiation of 
AZT therapy. Female patient has been found to 
be a risk factor for anemia in some studies.6-8
Another factor currently associated with 
anemia in HIV patients is CD4 cell counts. It 
was reported that 3.2% of asymptomatic HIV-
seropositive patients with CD4 cell counts 
greater than 700 cells/mm3were anemic, 
where as anemia was observed in 20.9% of 
those with CD4 cell counts less than 249 cells/
mm3. 9 Furthermore, CD4 cell counts less than 
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200 cells/mm3 was reported as a risk factor 
associated with anemia in HIV patients. 
Anemia was observed in 91.4% of HIV-
seropositive patients with CD4 cell counts 
less than 200 cells/mm3. 8,10 This study was 
conducted to evaluate therisk of anemia 
in human immunodeficiency virus (HIV) 
infection patients with different CD4 cell 
counts after AZT therapy.  
MATERIALS AND METHODS
Research design and subjects
This retrospective cohort study was 
conducted using data from medical record of 
HIV patients who attended at Dr. Soetomo 
General Hospital, Surabaya between January 
2005 to August 2015. The subjects were 
selected with the inclusion criteria as follows 
HIV patients underwent AZT-based therapy, 
aged 21-50 years, having CD4 cell counts ≥ 
200 cell/mm3 before AZT-based antiretrovirus 
therapy (ART), having hemoglobin (Hb) level 
≥ 10 and body mass index (BMI) 19-25. The 
exclusion criteria were pregnant women, 
underwent cotrimoxazole therapy, suffered 
from tuberculosis and received oral anti 
tuberculosis drugs, suffered certain diseases 
causing anemia such as renal chronic diseases 
and worm infection. Written inform consent 
was obtained from patients. The protocol of 
the study was approved by the Medical and 
Health Research Ethics Committee, Faculty 
of Medicine, Universitas Gadjah Mada, 
Yogyakarta.
Procedure
Subjects who met the inclusion and 
exclusion criteria were divided into two 
groups. The first group was HIV patients 
with CD4 cell counts 200-350 cell/mm
3, and 
the second group was HIV patients with 
CD4 cell counts ≥350 cell/mm
3. All available 
demographics (age, gender, body height and 
body weight), clinical (history of diseases 
and history of treatment) and laboratory (viral 
load counts, CD4 cell counts and Hb level) 
data of subjects before AZT-based ART were 
then recorded. After AZT-based ART for six 
months, clinical and laboratory data of both 
groups were monitored and recorded again. A 
number of additional factors that considered 
as potential confounders were recorded such 
as opportunistic infections, renal insufficiency 
were recorded and analyzed. 
Data analysis
All recorded demographics, clinical 
and laboratory data were presented as mean 
± standard deviation (SD) or number and 
percentage. Univariate analysis was applied 
to evaluate the demographics, clinical and 
laboratory data. Bivariate analysis such as 
chi-square ort-test was applied to evaluate 
the mean Hb level reduction and Hb level 
time reduction between group. Multivariate 
analysis using analysis of variance (ANOVA) 
was applied to evaluate the relationship 
between confounding factors and dependent 
variable.p value less than 0.05 was considered 
statistically significant.
RESULTS
During the study period 97 HIV patients 
who underwent AZT based ART were included 
in this study. Of these included patients, 50 
(51.5%) were male and 47 (48.5%) female. 
The age of patients ranged from 26 to 46 
years old. Most of these included patients had 
body weight ranged from 40 to 60 kg and in 
stage III of HIV infection. Furthermore, most 
of these included patients suffered from HIV 
infection through heterosexual transmission.
J Med Sci, Volume 49, No. 1, 2017 January: 23-30
26
TABLE 1.  HIV patient characteristics who underwent 
AZT based ART in Dr. Soetomo General 
Hospital, Surabaya between January 2008 
and August 2015.
Characteristics n (%)
Gender
•	 Man 50(51.5)
•	 Woman 47(48.5)
Age (years)
•	 > 46 18(18.6)
•	 46-26 68(70.1)
•	 < 26 11(11.3)
Education
•	 Elementary School 11(11.3)
•	 Secondary School 23(23.7)
•	 Senior High School 46(47.4)
•	 University 17(17.5)
Occupation
•	 Employees 65 (67.0)
•	 Daily labor 18(18.6)
•	 Permanent employment 23(23.7)
•	 Private employment 1(1.0)
•	 Unemployment 33 (33.0)
Clinical stage
•	 I 22 (22.7)
•	 II 16 (16.5)
•	 III 42 (43.3)
•	 IV 17 (17.5)
Body Weights (kg)
•	 <40 7 (7.2)
•	 40 – 60 71 (7.2)
•	 >60 19 (9.6)
Transmission
•	 Heterosexual 51(52.6)
•	 Homosexual 18(18.6)
•	 Heterosexual + homosexual 18(18.6)
•	 Drug ubuse 1(1.0)
•	 Transfusion 2(2.1)
•	 Heterosexual, + drug ubuse 6(6.2)
•	 Unknown 2(2.1)
This result showed that the anemia 
incidence significantly increased after AZT 
based ART comparae to beforethose both in 
HIV patients with CD4 cell counts 200-350 
cell/mm3and those ≥350 cell/mm3 (TABLE 
2). However, it was not affected by the level 
of CD4 cell counts.The anemia incidence on 
patients with CD4 cell counts 200-350 cell/
mm3 was not significantly different compared 
to those with CD4 cell counts >350 cell/mm
3 
(TABLE 3). 
TABLE 2.  Hemoglobin level of HIV patients before 
and after AZT based ART in CD4 cell 
counts 200-350 cell/mm3and >350 cell/
mm3 in Dr. Soetomo General Hospital, 
Surabaya between January 2005 and 
August 2008
Hb level Before AZT
After 
AZT Total p
CD4200-350
•	 Severe 5 13 18
<0.05
•	 Moderate 2 23 25
•	 Mild 5 11 16
•	 Very mild 17 14 31
•	 Normal 32 0 32
CD4> 350
•	 Severe 0 6 6
< 
0.001
•	 Moderate 4 12 16
•	 Mild 4 9 13
•	 Very mild 7 9 16
•	 Normal 21 0 21
chi-square with p<0.05
The CD4 cell counts, gender, age, body 
weight and clinical stage were not associated 
with the anemia incidence in HIV patients 
after AZT based ART (TABLE 4). However, 
the anemia incidence in those patients was 
significantly associated with the level of Hb 
before AZT based ART (p<0.05).
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TABLE 3.  Hemoglobin level of HIV patients with different level of CD4 cell counts before and after AZT based 
ART in Dr. Soetomo General Hospital, Surabaya between January 2005 and August 2008
Hb level 
CD4 cell counts (cell/mm3) RR
95% CI p200 - 350
n (%)
> 350
n (%)
Hb before AZT
•	 Severe 5 0 3.94 (0.41-93.15)
0.185
•	 Moderate 2 4 0.33 (0.04-2.38)
•	 Mild 5 4 0.82 (0.016-4.21)
•	 Very mild 17 7 0.59 (0.51-5.13)
•	 Normal 32 21 1
Hb after AZT
•	 Severe 13 6 1.39 (0.32-6.08)
0.815
•	 Moderate 23 12 1.23 (0.36-4.21)
•	 Mild 11 9 0.79 (0.20-3.14)
•	 Very mild 14 9 1
   chi-square with p<0.05
TABLE 4.  The relationship of patients’ predictors to anemia incidence in HIV patients after AZT based ART in 
Dr. Soetomo General Hospital, Surabaya between January 2008 and August 2015
Variable
Hb level*
RR (95% CI) p**Anemia 
n (%)
Normal
n (%)
CD4 (sel/mm3)
•	 200 – 350 43 (70.5%) 18 (29.5%) 0.919 (0.369-2.291)
0.523
•	 > 350 26 (72.2%) 10 (27.8%) 1
Gender
•	 Man 35 (70.0%) 15 (30.0%) 0.892 (0.370-2.151)
0.488
•	 Woman 34 (72.3%) 13 (27.7%) 1
Age (years)
•	 > 46 15 (83.3%) 3 (16.7%) 1.88 (0.22-16.14)
0.423•	 46-26 46 (67.6%) 22 (32.4%) 0.78 (0.15-3.74)
•	 < 26 8 (72.7%) 3 (27.3%) 1
Weight (kg)
•	 < 40 6 (85.7%) 1 (14.3%) 1.6 (0.11-46.01)
0.423•	 40-60 48 (67.6%) 23 (32.4%) 0.56 (0.14-2.08)
•	 > 60 15 (78.9%) 4 (21.1%) 1
Clinical stage
•	 3 – 4 43 (72.9%) 16 (27.1%) 1.240 (0.508-3.029)
0.401
•	 1 – 2 26 (68.4%) 12 (31.6%) 1
Hb before AZT  (g/dL)
•	 Anemia 45 (80.4%) 11 (19.6%) 2.898 (1.171-7.169)
0.017
•	 Normal 24 (58.5%) 17 (41.5%) 1
* anemia if Hb level < 10 g/dL and normal if >10 g/dL; **chi-square with p<0.05
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No significant difference in mean 
reduction and time reduction of Hb level 
between HIV patients with CD4 cell counts 
of 200- 350 cells/mm3and those with CD4 cell 
counts >350 cells/mm3were observed in this 
study (TABLE 5 and 6).
TABLE 5.  Mean Hb level reduction (mean ± SD) before and after AZT based ART of HIV patients 
with different CD4 cell counts in Dr. Soetomo General Hospital between January 2008 and 
August 2015
Hb’s level
CD4 cell counts Mean diff (95% CI) p
200-350(n=61) >350(n=36)
Before 11.34 ± 1.82 11.67 ±1.69 -0.322 (-1.061-0.416) 0.388
After 8.14 ± 2.16 8.41 ± 2.25 -0.265 (-1.180-0.651) 0.568
Mean reduction 3.20 ± 2.11 3.26 ± 2.24 -0.058 (-1.180-0.651) 0.899
t-test with p<0.05
TABLE 6.  Time reduction of Hb level (days) after AZT based in HIV patients in 
Dr. Soetomo General Hospital, Surabaya between January 2008 and 
August 2015
CD4 cell counts Mean diff
(95% CI)
p
200-350(n=61) >350(n=36)
34.03±23.01 37±21.27 -3.467(-12.809-5.874) 0.463
t-test with p<0.05
DISCUSSION
This study showed that the anemia 
incidence significantly increased after AZT 
based ART in HIV patients (TABLE 2).It is 
ndicated that AZT can induce anemia in HIV 
patients. Zidovudine treatment is associated 
with bone marrow suppression and an increased 
risk of developing anemia.1This result is 
suported with the previous studies reported 
by some authors. Women’s Interagency 
HIV Study (WIHS) reported the presence 
of anemia in 42.6% of HIV-infected women 
patients receiving AZT therapy compared 
with 34.3% of those not receiving AZT.3 
Furthermore, Agarwal et al.11 reported a high 
incidence of AZT-induced anemia (42.7%) 
in HIV-infected patients from eastern part of 
India. In contrast Semba et al.12 reported that, 
although the use of zidovudine was associated 
with an increased risk of anemia in the pre-
HAART era (1993–1996), use of zidovudine 
during the HAART era (1996–2000) was not 
significantly associated with anemia.
The study also showed that the anemia 
incidence was not associated with the level 
of CD4 cell counts. The anemia incidence on 
patients with CD4 cell counts 200-350 cell/
mm3 was not significantly different compared 
to those with CD4 cell counts >350 cell/mm
3 
(TABLE 3). It indicated that anemia incidence 
in HIV patients is not affected by the level 
of CD4 cell counts. The association between 
CD4 cell counts and anemia incidince is not 
clear. Previous studies the decrease of CD4 
cell counts was independently associated with 
the increase of anemia risk.Anemia affected 
30% of HIV patients with CD4 cell counts 
≥ 500 cell/mm3 and 63-95% of those with 
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CD4 cell counts < 200 cell/mm
3.8 In addition, 
anemia more frequent affected HIV patients 
with CD4 cell counts < 350 cell/mm
3.13 In 
contrast, another study reported that there was 
no association between anemia incidence and 
CD4 cell counts.
14Similarly a study among 
pregnant HIV positive women reported that 
there was no significant association between 
Hb level and CD4 cell counts.15
Although gender, age, weight and clinical 
stage have reported as risk factor for anemia 
in HIV patients in previous studies, 1,3,4,16 in 
the present study did not find as risk factor. 
However, the level of Hb before based ART 
has been found as risk factor in this study. The 
different in study designs, methodologies use 
including inclusion and exclusion criteria and 
cut-offs used to define anemia may contribute 
to these defferences.
CONCLUSION
In conclusion, there are no differences in 
the risk of anemia, a mean reduction of Hb 
level and time reduction of Hb level between 
HIV patients after AZT based ART with 
CD4 cell counts 200-350 cell/mm
3 and those 
CD4 cell counts >350 cell/mm
3. The anemia 
incidence in HIV patients after AZT based 
ART is associated with the Hb levels before 
AZT therapy.
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